The liver-brain axis of alcohol-mediated neurodegeneration: Role of toxic lipids

International Journal of Environmental Research and Public Health

Volumn 6, Issue 7, 2009, Pages 2055-2075

  De La Monte, Suzanne M ^a,b   Longato, Lisa ^a   Tong, Ming ^a,b   Denucci, Sarah ^a,b   Wands, Jack R ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Alcoholic liver disease; Ceramides; Ethanol; Insulin resistance; Neurodegeneration; Steatohepatitis

Indexed keywords

ALCOHOL; CERAMIDE; INSULIN GROWTH FACTOR 1; LIPID; SOMATOMEDIN; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN LEVEL; COGNITIVE DEFECT; FATTY LIVER; HEPATITIS; HEREDITY; HUMAN; INSULIN RESISTANCE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; REVIEW;

ALCOHOLISM; BRAIN; CERAMIDES; ETHANOL; FATTY LIVER, ALCOHOLIC; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; LIVER; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 68249128179     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph6072055     Document Type: Review

References (116)

1. Diehl, A.M.; Thorgeirsson, S.S.; Steer, C.J. Ethanol inhibits liver regeneration in rats without reducing transcripts of key protooncogenes. Gastroenterology 1990, 99, 1105-1112.
2. Duguay, L.; Coutu, D.; Hetu, C.; Joly, J.G. Inhibition of liver regeneration by chronic alcohol administration. Gut 1982, 23, 8-13.
3. Wands, J.R.; Carter, E.A.; Bucher, N.L.; Isselbacher, K.J. Inhibition of hepatic regeneration in rats by acute and chronic ethanol intoxication. Gastroenterology 1979, 77, 528-531.
4. Wands, J.R.; Carter, E.A.; Bucher, N.L.; Isselbacher, K.J. Effect of acute and chronic ethanol intoxication on hepatic regeneration. Adv. Exp. Med. Biol. 1980, 132, 663-670.
5. Banerjee, K.; Mohr, L.; Wands, J.R.; de la Monte, S.M. Ethanol inhibition of insulin signaling in hepatocellular carcinoma cells. Alcohol Clin. Exp. Res. 1998, 22, 2093-2101.
6. Carter, E.A.; Wands, J.R. Ethanol inhibits hormone stimulated hepatocyte DNA synthesis. Biochem. Biophys. Res. Commun. 1985, 128, 767-774.
7. Li, W.; Liu, X.; Yanoff, M. Phosphatidylcholine hydrolysis and DNA synthesis in cultured retinal capillary pericytes. Microvasc. Res. 1995, 49, 350-363.
8. Mohr, L.; Tanaka, S.; Wands, J.R. Ethanol inhibits hepatocyte proliferation in insulin receptor substrate 1 transgenic mice. Gastroenterology 1998, 115, 1558-1565.
9. Sasaki, Y.; Hayashi, N.; Ito, T.; Fusamoto, H.; Kamada, T.; Wands, J.R. Influence of ethanol on insulin receptor substrate-1-mediated signal transduction during rat liver regeneration. Alcohol Alcoholism 1994, 1, 99-106.
10. Sasaki, Y.; Wands, J.R. Ethanol impairs insulin receptor substrate-1 mediated signal transduction during rat liver regeneration. Biochem. Biophys. Res. Commun. 1994, 199, 403-409.
11. de la Monte, S.M.; Yeon, J.E.; Tong, M.; Longato, L.; Chaudhry, R.; Pang, M.Y.; Duan, K.; Wands, J.R. Insulin resistance in experimental alcohol-induced liver disease. J. Gastroenterol. Hepatol. 2008, 23, e477-86.
12. Pang, M.; de la Monte, S.M.; Longato, L.; Tong, M.; He, J.; Chaudhry, R.; Duan, K.; Ouh, J.; Wands, J.R. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J. Hepatol. 2009, 50, 1192-1201.
13. Harper, C. The neuropathology of alcohol-specific brain damage, or does alcohol damage the brain? J. Neuropathol. Exp. Neurol. 1998, 57, 101-110.
14. Harper, C.; Dixon, G.; Sheedy, D.; Garrick, T. Neuropathological alterations in alcoholic brains. Studies arising from the New South Wales Tissue Resource Centre. Prog. Neuropsychopharmacol. Biol. Psychiat. 2003, 27, 951-961.
15. de la Monte, S.M. Disproportionate atrophy of cerebral white matter in chronic alcoholics. Arch. Neurol. 1988, 45, 990-992.
16. Cohen, A.C.; Tong, M.; Wands, J.R.; de la Monte, S.M. Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin. Exp. Res. 2007, 31, 1558-1573.
17. de la Monte, S.M.; Wands, J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis. 2005, 7, 45-61.
18. Chang, L.; Chiang, S.H.; Saltiel, A.R. Insulin signaling and the regulation of glucose transport. Mol. Med. 2004, 10, 65-71.
19. Giovannone, B.; Scaldaferri, M.L.; Federici, M.; Porzio, O.; Lauro, D.; Fusco, A.; Sbraccia, P.; Borboni, P.; Lauro, R.; Sesti, G. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab. Res. Rev. 2000, 16, 434-441.
20. Gammeltoft, S.; Fehlmann, M.; Van, O.E. Insulin receptors in the mammalian central nervous system: binding characteristics and subunit structure. Biochimie 1985, 67, 1147-1153.
21. Hill, J.M.; Lesniak, M.A.; Pert, C.B.; Roth, J. Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 1986, 17, 1127-1138.
22. Broughton, S.K.; Chen, H.; Riddle, A.; Kuhn, S.E.; Nagalla, S.; Roberts, C.T., Jr.; Back, S.A. Large-scale generation of highly enriched neural stem-cell-derived oligodendroglial cultures: maturation-dependent differences in insulin-like growth factor-mediated signal transduction. J. Neurochem. 2007, 100, 628-638.
23. Freude, S.; Leeser, U.; Muller, M.; Hettich, M.M.; Udelhoven, M.; Schilbach, K.; Tobe, K.; Kadowaki, T.; Kohler, C.; Schroder, H.; Krone, W.; Bruning, J.C.; Schubert, M. IRS-2 branch of IGF-1 receptor signaling is essential for appropriate timing of myelination. J. Neurochem. 2008, 107, 907-917.
24. Joseph D'Ercole, A.; Ye, P. Expanding the mind: insulin-like growth factor I and brain development. Endocrinology 2008, 149, 5958-5962.
25. Schubert, M.; Brazil, D.P.; Burks, D.J.; Kushner, J.A.; Ye, J.; Flint, C.L.; Farhang-Fallah, J.; Dikkes, P.; Warot, X.M.; Rio, C.; Corfas, G.; White, M.F. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 2003, 23, 7084-7092.
26. Chesik, D.; de Keyser, J.; Wilczak, N. Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J. Mol. Neurosci. 2008, 35, 81-90.
27. Gong, X.; Xie, Z.; Zuo, H. Invivo insulin deficiency as a potential etiology for demyelinating disease. Med. Hypotheses 2008, 71, 399-403.
28. Liang, G.; Cline, G.W.; Macica, C.M. IGF-1 stimulates de novo fatty acid biosynthesis by Schwann cells during myelination. Glia 2007, 55, 632-641.
29. Ye, P.; Kollias, G.; D'Ercole, A.J. Insulin-like growth factor-I ameliorates demyelination induced by tumor necrosis factor-alpha in transgenic mice. J. Neurosci. Res. 2007, 85, 712-722.
30. Wands, J.R.; Mohr, L.; Banerjee, K.; Ganju, N.; Tanaka, S.; de la Monte, S.M. Ethanol and IRS-1 protein in the liver and brain. In Proceedings on Signal Transduction and Alcohol, Lund, Sweden, 2001.
31. Yeon, J.E.; Califano, S.; Xu, J.; Wands, J.R.; De La Monte, S.M. Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology 2003, 38, 703-714.
32. Ronis, M.J.; Butura, A.; Korourian, S.; Shankar, K.; Simpson, P.; Badeaux, J.; Albano, E.; Ingelman-Sundberg, M.; Badger, T.M. Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition. Exp. Biol. Med. (Maywood) 2008, 233, 344-355.
33. de la Monte, S.M.; Wands, J.R. Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons. CMLS, Cell Mol. Life Sci. 2002, 59, 882-893.
34. de la Monte, S.M.; Xu, X.J.; Wands, J.R. Ethanol inhibits insulin expression and actions in the developing brain. Cell Mol. Life Sci. 2005, 62, 1131-1145.
35. de la Monte, S.M.; Tong, M.; Cohen, A.C.; Sheedy, D.; Harper, C.; Wands, J.R. Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. Alcohol Clin. Exp. Res. 2008, 32, 1630-1644.
36. Soscia, S.J.; Tong, M.; Xu, X.J.; Cohen, A.C.; Chu, J.; Wands, J.R.; de la Monte, S.M. Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. Cell Mol. Life Sci. 2006, 63, 2039-2056.
37. Ronis, M.J.; Wands, J.R.; Badger, T.M.; de la Monte, S.M.; Lang, C.H.; Calissendorff, J. Alcohol-induced disruption of endocrine signaling. Alcohol Clin. Exp. Res. 2007, 31, 1269-1285.
38. Enomoto, N.; Takei, Y.; Hirose, M.; Konno, A.; Shibuya, T.; Matsuyama, S.; Suzuki, S.; Kitamura, K.I.; Sato, N. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J. Pharmacol. Exp. Ther. 2003, 306, 846-854.
39. Onishi, Y.; Honda, M.; Ogihara, T.; Sakoda, H.; Anai, M.; Fujishiro, M.; Ono, H.; Shojima, N.; Fukushima, Y.; Inukai, K.; Katagiri, H.; Kikuchi, M.; Oka, Y.; Asano, T. Ethanol feeding induces insulin resistance with enhanced PI 3-kinase activation. Biochem. Biophys. Res. Commun. 2003, 303, 788-794.
40. Patel, B.C.; D'Arville, C.; Iwahashi, M.; Simon, F.R. Impairment of hepatic insulin receptors during chronic ethanol administration. Am. J. Physiol. 1991, 261, G199-205.
41. Sadri, P.; Legare, D.J.; Takayama, S.; Lautt, W.W. Increased incidence of hepatic insulin-sensitizing substance (HISS)-dependent insulin resistance in female rats prenatally exposed to ethanol. Can. J. Physiol. Pharmacol. 2005, 83, 383-387.
42. Tomita, K.; Azuma, T.; Kitamura, N.; Nishida, J.; Tamiya, G.; Oka, A.; Inokuchi, S.; Nishimura, T.; Suematsu, M.; Ishii, H. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 2004, 126, 873-885.
43. Yao, X.H.; Chen, L.; Nyomba, B.L. Adult rats prenatally exposed to ethanol have increased gluconeogenesis and impaired insulin response of hepatic gluconeogenic genes. J. Appl. Physiol. 2006, 100, 642-648.
44. Li, X.L.; Man, K.; Ng, K.T.; Sun, C.K.; Lo, C.M.; Fan, S.T. The influence of phosphatidylinositol 3-kinase/Akt pathway on the ischemic injury during rat liver graft preservation. Am. J. Transplant. 2005, 5, 1264-1275.
45. Michl, P.; Downward, J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z. Gastroenterol. 2005, 43, 1133-1139.
46. Roberts, R.A.; James, N.H.; Cosulich, S.C. The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor alpha-mediated rat hepatocyte survival and apoptosis. Hepatology 2000, 31, 420-427.
47. Rust, C.; Bauchmuller, K.; Fickert, P.; Fuchsbichler, A.; Beuers, U. Phosphatidylinositol 3-kinase-dependent signaling modulates taurochenodeoxycholic acid-induced liver injury and cholestasis in perfused rat livers. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289, G88-94.
48. Valverde, A.M.; Fabregat, I.; Burks, D.J.; White, M.F.; Benito, M. IRS-2 mediates the antiapoptotic effect of insulin in neonatal hepatocytes. Hepatology 2004, 40, 1285-1294.
49. Carmiel-Haggai, M.; Cederbaum, A.I.; Nieto, N. Binge ethanol exposure increases liver injury in obese rats. Gastroenterology 2003, 125, 1818-1833.
50. McVicker, B.L.; Tuma, D.J.; Kubik, J.L.; Tuma, P.L.; Casey, C.A. Ethanol-induced apoptosis in polarized hepatic cells possibly through regulation of the Fas pathway. Alcohol Clin. Exp. Res. 2006, 30, 1906-1915.
51. de la Monte, S.M.; Ganju, N.; Banerjee, K.; Brown, N.V.; Luong, T.; Wands, J.R. Partial rescue of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase. Alcohol Clin. Exp. Res. 2000, 24, 716-726.
52. de la Monte, S.M.; Neely, T.R.; Cannon, J.; Wands, J.R. Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons. Cell Mol. Life Sci. 2001, 58, 1950-1960.
53. Hallak, H.; Seiler, A.E.; Green, J.S.; Henderson, A.; Ross, B.N.; Rubin, R. Inhibition of insulin-like growth factor-I signaling by ethanol in neuronal cells. Alcohol Clin. Exp. Res. 2001, 25, 1058-1064.
54. Zhang, F.X.; Rubin, R.; Rooney, T.A. Ethanol induces apoptosis in cerebellar granule neurons by inhibiting insulin-like growth factor 1 signaling. J. Neurochem. 1998, 71, 196-204.
55. Spaissman, A.; Tong, M.; de la Monte, S.M. Acetaldehyde-Mediated neuronal apoptosis and mitochondrial dysfunction: relevance to fetal alcohol syndrome. J. Neurochem. 2009, (Submitted).
56. Ramachandran, V.; Perez, A.; Chen, J.; Senthil, D.; Schenker, S.; Henderson, G.I. In utero ethanol exposure causes mitochondrial dysfunction, which can result in apoptotic cell death in fetal brain: a potential role for 4-hydroxynonenal. Alcohol Clin. Exp. Res. 2001, 25, 862-871.
57. Ikonomidou, C.; Bittigau, P.; Ishimaru, M.J.; Wozniak, D.F.; Koch, C.; Genz, K.; Price, M.T.; Stefovska, V.; Horster, F.; Tenkova, T.; Dikranian, K.; Olney, J.W. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 2000, 287, 1056-1060.
58. de la Monte, S.M.; Wands, J.R. Mitochondrial DNA damage and impaired mitochondrial function contribute to apoptosis of insulin-stimulated ethanol-exposed neuronal cells. Alcohol Clin. Exp. Res. 2001, 25, 898-906.
59. Xu, J.; Yeon, J.E.; Chang, H.; Tison, G.; Chen, G.J.; Wands, J.; de la Monte, S. Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J. Biol. Chem. 2003, 278, 26929-26937.
60. Marco, C.; Ceacero, F.; Gonzalez-Pacanowska, D.; Garcia-Peregrin, E.; Segovia, J.L. Alterations induced by chronic ethanol treatment on lipid composition of microsomes, mitochondria and myelin from neonatal chick liver and brain. Biochem. Int. 1986, 12, 51-60.
61. Muller, G.; Jung, C.; Frick, W.; Bandlow, W.; Kramer, W. Interaction of phosphatidylinositolglycan(-peptides) with plasma membrane lipid rafts triggers insulin-mimetic signaling in rat adipocytes. Arch. Biochem. Biophys. 2002, 408, 7-16.
62. Lutchman, G.; Promrat, K.; Kleiner, D.E.; Heller, T.; Ghany, M.G.; Yanovski, J.A.; Liang, T.J.; Hoofnagle, J.H. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol. 2006, 4, 1048-1052.
63. Promrat, K.; Lutchman, G.; Uwaifo, G.I.; Freedman, R.J.; Soza, A.; Heller, T.; Doo, E.; Ghany, M.; Premkumar, A.; Park, Y.; Liang, T.J.; Yanovski, J.A.; Kleiner, D.E.; Hoofnagle, J.H. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39, 188-196.
64. Capeau, J. Insulin resistance and steatosis in humans. Diabetes Metab. 2008, 34, 649-657.
65. Leonard, B.L.; Watson, R.N.; Loomes, K.M.; Phillips, A.R.; Cooper, G.J. Insulin resistance in the Zucker diabetic fatty rat: a metabolic characterisation of obese and lean phenotypes. Acta Diabetol. 2005, 42, 162-170.
66. Kraegen, E.W.; Cooney, G.J. Free fatty acids and skeletal muscle insulin resistance. Curr. Opin. Lipidol. 2008, 19, 235-241.
67. Kao, Y.; Youson, J.H.; Holmes, J.A.; Al-Mahrouki, A.; Sheridan, M.A. Effects of insulin on lipid metabolism of larvae and metamorphosing landlocked sea lamprey, Petromyzon marinus. Gen. Comp. Endocrinol. 1999, 114, 405-414.
68. Holland, W.L.; Summers, S.A. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 2008, 29, 381-402.
69. Langeveld, M.; Aerts, J.M. Glycosphingolipids and insulin resistance. Prog. Lipid. Res. 2009, 48, 196-205.
70. Summers, S.A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid. Res. 2006, 45, 42-72.
71. Boden, G. Ceramide: a contributor to insulin resistance or an innocent bystander? Diabetologia 2008, 51, 1095-1096.
72. Delarue, J.; Magnan, C. Free fatty acids and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10, 142-148.
73. Holland, W.L.; Brozinick, J.T.; Wang, L.P.; Hawkins, E.D.; Sargent, K.M.; Liu, Y.; Narra, K.; Hoehn, K.L.; Knotts, T.A.; Siesky, A.; Nelson, D.H.; Karathanasis, S.K.; Fontenot, G.K.; Birnbaum, M.J.; Summers, S.A. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007, 5, 167-179.
74. Holland, W.L.; Knotts, T.A.; Chavez, J.A.; Wang, L.P.; Hoehn, K.L.; Summers, S.A. Lipid mediators of insulin resistance. Nutr. Rev. 2007, 65, S39-46.
75. Anderson, N.; Borlak, J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 2008, 60, 311-357.
76. Kaplowitz, N.; Than, T.A.; Shinohara, M.; Ji, C. Endoplasmic reticulum stress and liver injury. Semin. Liver Dis. 2007, 27, 367-377.
77. Malhi, H.; Gores, G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 2008, 28, 360-369.
78. Sundar Rajan, S.; Srinivasan, V.; Balasubramanyam, M.; Tatu, U. Endoplasmic reticulum (ER) stress & diabetes. Indian J. Med. Res. 2007, 125, 411-424.
79. Bourbon, N.A.; Sandirasegarane, L.; Kester, M. Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. J. Biol. Chem. 2002, 277, 3286-3292.
80. Hajduch, E.; Balendran, A.; Batty, I.H.; Litherland, G.J.; Blair, A.S.; Downes, C.P.; Hundal, H.S. Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 2001, 44, 173-183.
81. Nogueira, T.C.; Anhe, G.F.; Carvalho, C.R.; Curi, R.; Bordin, S.; Carpinelli, A.R. Involvement of phosphatidylinositol-3 kinase/AKT/PKCzeta/lambda pathway in the effect of palmitate on glucose-induced insulin secretion. Pancreas 2008, 37, 309-315.
82. Powell, D.J.; Hajduch, E.; Kular, G.; Hundal, H.S. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol. Cell Biol. 2003, 23, 7794-7808.
83. Consitt, L.A.; Bell, J.A.; Houmard, J.A. Intramuscular lipid metabolism, insulin action, and obesity. IUBMB Life 2009, 61, 47-55.
84. Vistisen, B.; Hellgren, L.I.; Vadset, T.; Scheede-Bergdahl, C.; Helge, J.W.; Dela, F.; Stallknecht, B. Effect of gender on lipid-induced insulin resistance in obese subjects. Eur. J. Endocrinol. 2008, 158, 61-68.
85. Zierath, J.R. The path to insulin resistance: paved with ceramides? Cell Metab. 2007, 5, 161-163.
86. Adibhatla, R.M.; Hatcher, J.F. Altered lipid metabolism in brain injury and disorders. Subcell Biochem. 2008, 49, 241-268.
87. Blakemore, W.F.; Franklin, R.J. Remyelination in experimental models of toxin-induced demyelination. Curr. Top Microbiol. Immunol. 2008, 318, 193-212.
88. Daigo, M.; Arai, Y.; Oshida, K.; Kitamura, Y.; Hayashi, M.; Shimizu, T.; Yamashiro, Y. Effect of hypoxic-ischemic injury on serine palmitoyltransferase activity in the developing rat brain. Pathobiology 2008, 75, 330-334.
89. Soeda, S.; Tsuji, Y.; Ochiai, T.; Mishima, K.; Iwasaki, K.; Fujiwara, M.; Yokomatsu, T.; Murano, T.; Shibuya, S.; Shimeno, H. Inhibition of sphingomyelinase activity helps to prevent neuron death caused by ischemic stress. Neurochem. Int. 2004, 45, 619-626.
90. Soriano, J.M.; Gonzalez, L.; Catala, A.I. Mechanism of action of sphingolipids and their metabolites in the toxicity of fumonisin B1. Prog. Lipid. Res. 2005, 44, 345-356.
91. Adams, J.M., II; Pratipanawatr, T.; Berria, R.; Wang, E.; DeFronzo, R.A.; Sullards, M.C.; Mandarino, L.J. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004, 53, 25-31.
92. Aerts, J.M.; Ottenhoff, R.; Powlson, A.S.; Grefhorst, A.; van Eijk, M.; Dubbelhuis, P.F.; Aten, J.; Kuipers, F.; Serlie, M.J.; Wennekes, T.; Sethi, J.K.; O'Rahilly, S.; Overkleeft, H.S. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 2007, 56, 1341-1349.
93. JeBailey, L.; Wanono, O.; Niu, W.; Roessler, J.; Rudich, A.; Klip, A. Ceramide- and oxidant-induced insulin resistance involve loss of insulin-dependent Rac-activation and actin remodeling in muscle cells. Diabetes 2007, 56, 394-403.
94. Schmitz-Peiffer, C.; Craig, D.L.; Biden, T.J. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J. Biol. Chem. 1999, 274, 24202-24210.
95. Teruel, T.; Hernandez, R.; Lorenzo, M. Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 2001, 50, 2563-25671.
96. Tong, M.; de la Monte, S.M. Mechanisms of ceramide-mediated neurodegeneration. J. Alzheimers Dis. 2009, 16, 705-714.
97. Schmidt, K.S.; Gallo, J.L.; Ferri, C.; Giovannetti, T.; Sestito, N.; Libon, D.J.; Schmidt, P.S. The neuropsychological profile of alcohol-related dementia suggests cortical and subcortical pathology. Dement. Geriatr. Cogn. Disord 2005, 20, 286-291.
98. Kopelman, M.D.; Thomson, A.D.; Guerrini, I.; Marshall, E.J. The Korsakoff syndrome: clinical aspects, psychology and treatment. Alcohol Alcoholism 2009, 44, 148-154.
99. Elwing, J.E.; Lustman, P.J.; Wang, H.L.; Clouse, R.E. Depression, anxiety, and nonalcoholic steatohepatitis. Psychosom. Med. 2006, 68, 563-569.
100. Loftis, J.M.; Huckans, M.; Ruimy, S.; Hinrichs, D.J.; Hauser, P. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci. Lett. 2008, 430, 264-268.
101. Perry, W.; Hilsabeck, R.C.; Hassanein, T.I. Cognitive dysfunction in chronic hepatitis C: a review. Dig. Dis. Sci. 2008, 53, 307-321.
102. Karaivazoglou, K.; Assimakopoulos, K.; Thomopoulos, K.; Theocharis, G.; Messinis, L.; Sakellaropoulos, G.; Labropoulou-Karatza, C. Neuropsychological function in Greek patients with chronic hepatitis C. Liver Int. 2007, 27, 798-805.
103. Weiss, J.J.; Gorman, J.M. Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr. HIV/AIDS Rep. 2006, 3, 176-181.
104. de la Monte, S.M.; Tong, M.; Lester-Coll, N.; Plater, M., Jr.; Wands, J.R. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimers Dis. 2006, 10, 89-109.
105. Lester-Coll, N.; Rivera, E.J.; Soscia, S.J.; Doiron, K.; Wands, J.R.; de la Monte, S.M. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimers Dis. 2006, 9, 13-33.
106. Tong, M.; Lawton, M.; Neusner, A.; Longato, L.; Wands, J.R.; de la Monte, S.M. Nitrosamine-mediated type 2 diabetes mellitus, hepatic steatosis, and alzheimer-type neurodegeneration: Potential role of environmental exposures in our insulin resistance diseases pandemic. J. Alzheimers Dis. 2009, (In Press).
107. Lyn-Cook, L.E.; Lawton, M.; Tong, M.; Silbermann, E.; Longato, L.; Jiao, P.; Mark, P.; Wands, J.R.; Xu, H.; de la Monte, S.M. Hepatic ceramide mediates brain insulin resistance and neurodegeneration in obesity with type 2 diabetes mellitus and Non-alcoholoic steatohepatitis. J. Alzheimers Dis. 2008, (Submitted).
108. Moroz, N.; Tong, M.; Longato, L.; Xu, H.; de la Monte, S.M. Limited Alzheimer-type neurodegeneration in experimental obesity and Type 2 diabetes mellitus. J. Alzheimers Dis. 2008, 15, 29-44.
109. Tong, M.; Longato, L.; de la Monte, S.M. Nitrosamine exposure exacerbates high fat diet-mediated neurodegeneration. BMC Cell Biol. 2009, (Under Review).
110. Tong, M.; Neusner, A.; Longato, L.; Lawton, M.; Wands, J.R.; de la Monte, S.M. Nitrosamine Exposure Causes Insulin Resistance Diseases: Relevance to Type 2 Diabetes Mellitus, Non-Alcoholic Steatohepatitis, and Alzheimer's Disease. J. Alzheimers Dis. 2009, Jun 19, (Epub ahead of print).
111. Tong, M.; Neusner, A.; Longato, L.; Lawton, M.; Wands, J.R.; de la Monte, S.M. Nitosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer disease. J. Alzheimers Dis. 2009, (In Press).
112. Arboleda, G.; Huang, T.J.; Waters, C.; Verkhratsky, A.; Fernyhough, P.; Gibson, R.M. Insulin-like growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur. J. Neurosci. 2007, 25, 3030-3038.
113. Chalfant, C.E.; Kishikawa, K.; Mumby, M.C.; Kamibayashi, C.; Bielawska, A.; Hannun, Y.A. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J. Biol. Chem. 1999, 274, 20313-20317.
114. Liu, B.; Obeid, L.M.; Hannun, Y.A. Sphingomyelinases in cell regulation. Semin. Cell Dev. Biol. 1997, 8, 311-322.
115. Bryan, L.; Kordula, T.; Spiegel, S.; Milstien, S. Regulation and functions of sphingosine kinases in the brain. Biochim. Biophys. Acta 2008, 1781, 459-466.
116. Van Brocklyn, J.R. Sphingolipid signaling pathways as potential therapeutic targets in gliomas. Mini. Rev. Med. Chem. 2007, 7, 984-990.